The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1730
June 9, 2025
View Complete Issue         Table of Contents 2019 
Guselkumab (Tremfya) — An IL-23 Antagonist for Crohn's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Guselkumab (Tremfya) — An IL-23 Antagonist for Crohn's Disease
June 9, 2025 (Issue: 1730)
The injectable interleukin (IL)-23 antagonist guselkumab (Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults; it was approved earlier for treatment of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Guselkumab (Tremfya) — An IL-23 Antagonist for Crohn's Disease
Article code: 1730c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.